The interaction of CD40 with CD154 is a pivotal trigger of immune cascade-inducing acute liver failure, however its clinical significance has not been well studied. The present study aimed to investigate the clinical implications of serum-soluble CD154 (sCD154) levels and the expression of CD40 on monocytes in patients with fulminant hepatic failure (FHF). The results showed that serum sCD154 levels and CD40 expression on monocytes were significantly higher in FHF patients than in acute hepatitis (AH) patients and healthy controls, and were also significantly higher in FHF patients who died, compared with those who survived. We conclude that high serum levels of sCD154 may be linked to fatal outcome in patients with severe liver injury and may be a valuable prognostic marker for survival in patients with FHF.
Introduction
Fulminant hepatic failure (FHF) is a lifethreatening condition that is induced by factors such as hepatitis virus infection or drug toxicity. Its underlying pathophysiological mechanisms are not fully understood, however uncontrolled hepatic immunoactivation is considered to be a pivotal mechanism of FHF. 1 -3 Studies indicate that intrahepatic up-regulation of the immunoactivating molecules, CD40 and CD154, might lead to excessive antigen presentation in FHF as an early step in its pathogenesis before the onset of tissue damage. 1 CD154 is a member of the tumour necrosis factor receptor superfamily and is expressed on activated CD4 + T cells and platelets. 4, 5 The CD40-CD154 interaction induces strong immunoactivation at different levels of the immune system, including T cells, B cells, macrophages and dendritic cells and, furthermore, CD154 stimulation of CD40 plays a central role in hepatocyte apoptosis in murine fulminant hepatitis. 6 The CD40-CD154 interaction is also a pivotal trigger of immune cascadeinducing FHF. 7 A recent study showed that levels of serum-soluble CD154 (sCD154) and matrix metalloproteinase 9 might help in providing additional information for assessment of cardiovascular risk stratification and prediction. 8 Although sCD154 has been observed in FHF for the past decade, its clinical significance has not been well studied. 1, 7 This study was, therefore, designed to investigate serum sCD154 levels and the expression of CD40 on monocytes in patients with FHF, and to test the hypothesis that sCD154 may predict clinical outcome in FHF. Acute
Patients and methods

PATIENTS
Blood samples were collected from patients with FHF and AH, and also from healthy controls. FHF was diagnosed according to the diagnostic criteria of the American Association for the Study of Liver Diseases: the most widely accepted definition of acute liver failure includes evidence of coagulation abnormality, usually an international normalized ratio (INR) ≥ 1.5, and any degree of mental alteration (encephalopathy) in a patient without pre-existing cirrhosis and an illness of < 26 weeks duration. 9 Healthy, ageand sex-matched volunteers were to be used as controls.
The study protocol was approved by the local ethics committee (The Third Affiliated Hospital of Sun Yat-Sen University) and all patients provided written informed consent to participate.
ISOLATION OF MONOCYTES
Peripheral blood mononuclear cells were isolated from fresh heparinized blood via Ficoll-Paque™ (StemCell Technologies Inc., Vancouver, Canada) separation. The cells were washed twice with phosphate-buffered saline (PBS; 10 mM, pH 7.2). and suspended in RPMI-1640 medium supplemented with 10% heat-inactivated fetal calf serum (Invitrogen™, Carlsbad, CA, USA) prior to further use.
DETECTION OF CD40 EXPRESSION ON MONOCYTES
Quantitative CD40 expression of monocytes was determined by flow cytometric assay (Becton Dickinson, Soochow, China). Briefly, at least 2 × 10 5 monocytes were harvested and resuspended in 0.1 ml PBS containing 1% bovine serum albumin (Sigma-Aldrich, Guangzhou, China). The cell suspension was incubated with 0.2 µg fluorescein isothiocyanate-conjugated primary antibody (mouse monoclonal anti-human CD40, 1:100 dilution) (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Samples were measured on a fluorescence-activated cell sorter (FACS) using CellQuest software (Becton Dickinson).
DETECTION OF SERUM SCD154
Serum concentrations of sCD154 were determined with a Quantikine human sCD154 immunoassay kit (R&D Systems, Minneapolis, MN, USA), performed according to the manufacturer's instructions. The sensitivity of detection of sCD154 was 4 pg/ml and the optical density was determined at 450 nm.
STATISTICAL ANALYSIS
All data are expressed as means ± SD. Data analysis was performed using the Student's ttest and the Mann-Whitney U-test, with Pvalues < 0.05 considered to be significant.
Results
Blood samples were collected from 25 patients with FHF, 28 patients with AH and 36 healthy controls matched for age (Table  1) . Several patients whose numerical data were incomplete were excluded from the analysis. This resulted in the FHF, AH groups and healthy volunteers not being matched for sex (male:female ratio). However, supplementary study showed that there was no significant difference in the serum levels of sCD154 between male and female subjects. The FHF cases included 10 surviving and 15 deceased patients. None of the AH patients had died. The aetiology of FHF was due to hepatitis E virus infection (n = 16), Predictive value of sCD154 in fulminant hepatic failure autoimmune hepatitis (n = 2) and unknown aetiology (n = 7): the aetiology of AH was due to hepatitis A virus infection (n = 4), hepatitis E virus infection (n = 8), druginduced hepatitis (n = 4) and unknown origin (n = 12).
SERUM LEVELS OF SCD154
The serum levels of sCD154 in FHF patients (3464.9 ± 674.5 pg/ml) were significantly higher than those in AH patients (1754.2 ± 574.6 pg/ml, P < 0.001) and the controls (1434.5 ± 373.9 pg/ml, P < 0.001). There was no significant difference in the serum levels of sCD154 between the AH patients and the controls (Fig. 1A) . Among the FHF patients, the serum levels of sCD154 in deceased patients were significantly higher than those in surviving patients (3980.9 ± 517.8 pg/ml versus 2880.6 ± 329.2 pg/ml, P < 0.01). The serum levels of sCD154 in surviving patients were significantly higher than those in healthy controls (P < 0.05) (Fig.1B) .
EXPRESSION OF CD40 ON MONOCYTES
Expression of CD40 on monocytes in patients with FHF and AH was significantly higher than the healthy controls (67.3 ± 16.2% and 50.8 ± 9.9% versus 5.3 ± 1.9%, P < 0.001) ( Fig. 2A) , while monocyte CD40 expression showed no difference between patients with FHF and AH. Monocyte CD40 expression was significantly higher in FHF patients who died, compared with surviving patients (71.2 ± 15.1% versus 48.2 ± 11.9%, P < 0.05). Expression of CD40 on monocytes in surviving patients was also significantly higher than those in healthy controls (P < 0.01) (Fig. 2B ).
Discussion
Among the FHF patients in this study, serum levels of sCD154 and expression of CD40 on monocytes were significantly higher in deceased compared with surviving patients, supporting the hypothesis that sCD154 may provide prognostic information in FHF. Uncontrolled hepatic immunoactivation is considered a pivotal pathomechanism of FHF, 1 -3 and CD40-CD154 interaction on dendritic cells and other antigen-presenting cells, such as monocytes/macrophages and B lymphocytes, has been shown to up-regulate co-stimulatory molecules CD80 and CD86 and, thus, enhance T cell activation. 10 Deletion of either the CD40 or CD154 gene resulted in severe immunodeficiency in mice. 11 The interaction of CD40 with CD154 is a pivotal trigger of the immune cascade that induces FHF. Schmitz et al., 7 in an overexpression of the CD40 ligand mouse model, reported that the CD40-CD154 system plays a pivotal pathogenic role in the development of FHF. Meanwhile, Mayo et al. 12 also reported that CD40-CD154 signals may be involved in immunoglobulin production within the liver of autoimmune liver diseases. Moreover, a recent study has shown that activation of CD40 on hepatocytes and cholangiocytes is critical for amplifying Fasmediated apoptosis in the human liver. 13 The clinical significance of sCD154 in liver diseases is, therefore, important and deserves close attention.
The current investigation has shown that the serum levels of soluble CD154 were significantly increased in FHF compared with age and gender-matched controls and AH patients, in agreement with a previous study. 1 Furthermore, we demonstrated that high levels of sCD154 are related to poor disease outcome and sCD154 may be valuable as a biomarker for rapid assessment of prognosis in patients with FHF. Lucidi et al. 14 reported that Clichy's and King's College criteria are the two main scoring systems used to select patients for liver transplantation. Both models achieve high specificity but remain associated with limited negative predictive value. Recent observations have shown that only dynamic evaluation of the model for endstage liver disease (MELD) scores, with its recalculation within the last 3 months, can be regarded as the best predictor for death on the waiting list for liver transplantation. 15 The accuracy of measuring sCD154 alone for the prediction of fatal outcome does not exceed that obtained by traditional scores, such as King's College criteria; 16 however, the use of sCD154 levels with King's College criteria or with other criteria such as MELD may improve sensitivity and the identification of patients early in the liver disease process. This should be prospectively validated.
We found that monocyte CD40 expression was significantly higher in FHF patients who died, compared with the surviving patients.
Zhou et al., 6 in a concanavalin A mouse model, reported that CD40-CD154 interaction plays a major role in triggering hepatocellular apoptosis through the Fas/FasL pathway. Recent studies indicate that the activation of CD40 on cholangiocytes by activated macrophages provides a molecular mechanism to amplify chronic inflammation and bile duct destruction in liver disease. 17 These results also suggest that CD40 expression on monocytes may be linked to poor prognosis in patients with liver diseases.
The finding of successively increased levels of sCD154 in healthy, AH and FHF patients may indicate a wider prognostic capability of sCD154, e.g. for the identification of acute liver diseases. Furthermore, the present observations in clinical patients and the findings of Leifeld et al. 1 in mice with FHF suggest that sCD154 may be used as a biomarker for dynamic monitoring of the immune status of acute liver diseases, and it may contribute to the estimation of risk of death in relation to other clinical or laboratory markers.
In conclusion, our current results suggest that sCD154 levels may be associated with the severity of acute liver diseases and that sCD154 may be a valuable prognostic marker for survival in patients with FHF.
